Clinical Trials
46 trialsA Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
Chinese PLA General Hospital
HLX301
Shanghai Henlius Biotech
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Telios Pharma, Inc.
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Kecellitics Biotech Company Ltd
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
ImmVira Pharma Co. Ltd
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
University of Aarhus
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
Eutilex
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Chinese PLA General Hospital
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
Tayu Huaxia Biotech Medical Group Co., Ltd.
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
The First Affiliated Hospital of Soochow University
An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Chinese PLA General Hospital
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
Affiliated Hospital to Academy of Military Medical Sciences
CAR-T
Shenzhen University General Hospital
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
Shenzhen Geno-Immune Medical Institute
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Kecellitics Biotech Company Ltd
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Southwest Hospital, China
A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Southwest Hospital, China
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
Shanghai Tongji Hospital, Tongji University School of Medicine
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Ruijin Hospital
Lonquek for Autologous Stem Cell Mobilization
Sheba Medical Center
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Second Affiliated Hospital of Guangzhou Medical University
CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Zhejiang University
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Peking University
Beta Alethine in Treating Patients With Low-Grade Lymphoma
National Cancer Institute (NCI)
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.
Maria Sklodowska-Curie National Research Institute of Oncology
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich